Retaining Patients with Drug-Resistant Tuberculosis on Treatment During the COVID-19 Pandemic — Dharavi, Mumbai, India, 2020–2022
MMWR. Morbidity and Mortality Weekly Report · 2023
DOI: 10.15585/mmwr.mm7212a2 ↗Kurz gefasst
Fachartikel in der Zeitschrift MMWR. Morbidity and Mortality Weekly Report, 2023. Verfasst von Mangala D Gomare und 14 weiteren Autor:innen. Hauptthemen laut MEDLINE: COVID-19, Tuberculosis, Multidrug-Resistant, Tuberculosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Mumbai, India's second largest city, has one of the highest prevalences of drug-resistant tuberculosis* (DRTB) in the world. Treatment for DRTB takes longer and is more complicated than treatment for drug-susceptible tuberculosis (TB). Approximately 300 persons receive a new DRTB diagnosis each year in Mumbai's Dharavi slum†; historically, fewer than one half of these patients complete DRTB treatment. As nationwide restrictions to mitigate the COVID-19 pandemic were implemented, a program to facilitate uninterrupted DRTB care for patients receiving treatment was also implemented. A comprehensive tool and risk assessment provided support to DRTB patients and linked those who relocated outside of Dharavi during the pandemic to DRTB care at their destination. During May 2020-September 2022, a total of 973 persons received DRTB treatment in Dharavi, including 255 (26%) who relocated during treatment. Overall, 25 (3%) DRTB patients were lost to follow-up, a rate substantially lower than the rate before the pandemic (18%). Proactive planning and implementation of simple tools retained patients on treatment during periods of travel restrictions and relocations, improving programmatic outcomes. This approach might aid public health programs serving migrant populations or patients receiving treatment for DRTB during public health emergencies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Gomare, M. D., Bhide, S., Deshmukh, R., Kaipilyawar, S., Puri, V., Moonan, P. K., Khetade, D. K., Nyendak, M., Yeldandi, V., Smith, J. P., Tobias, J. L., Date, A., Joshi, R., Kumar, R., & Ho, C. S. (2023). Retaining Patients with Drug-Resistant Tuberculosis on Treatment During the COVID-19 Pandemic — Dharavi, Mumbai, India, 2020–2022. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7212a2
Vancouver
Gomare MD, Bhide S, Deshmukh R, Kaipilyawar S, Puri V, Moonan PK, et al. Retaining Patients with Drug-Resistant Tuberculosis on Treatment During the COVID-19 Pandemic — Dharavi, Mumbai, India, 2020–2022. MMWR. Morbidity and Mortality Weekly Report. 2023. doi:10.15585/mmwr.mm7212a2
BibTeX
@article{Gomare2023,
author = {Gomare, Mangala D and Bhide, Sampada and Deshmukh, Rajesh and Kaipilyawar, Satish and Puri, Varsha and Moonan, Patrick K and Khetade, Dilip K and Nyendak, Melissa and Yeldandi, Vijay and Smith, Jonathan P and Tobias, James L and Date, Anand and Joshi, Rajendra and Kumar, Ravinder and Ho, Christine S},
title = {Retaining Patients with Drug-Resistant Tuberculosis on Treatment During the COVID-19 Pandemic — Dharavi, Mumbai, India, 2020–2022},
journal = {MMWR. Morbidity and Mortality Weekly Report},
year = {2023},
doi = {10.15585/mmwr.mm7212a2}
}
EUVIMED